Lowers the risk of MI, stroke, revascularization procedures, and angina. ANDA 209912, held by Graviti Pharms. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 209912 (Atorvastatin Calcium), held by Graviti Pharms, was first approved by FDA on Jun 18, 2018, with 7 approved supplements and 0 published complete response letters.
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 18, 2018 | Original application | Approved | None posted |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Jun 14, 2024 | Supplement 27Labeling · Standard review | Approved | None posted |
| Jul 10, 2023 | Supplement 23Labeling · Standard review | Approved | None posted |
| Nov 30, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 30, 2021 | Supplement 17Labeling · Standard review | Approved | None posted |
| Nov 30, 2021 | Supplement 18Labeling · Standard review | Approved | None posted |
| Aug 7, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 7, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 18, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters